GO:0004118 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004118 describes a phosphodiesterase catalytic activity that hydrolyzes nucleoside 3',5'-cyclic phosphates to nucleoside 5'-phosphates and is stimulated by cGMP.
• cGMP-stimulated cyclic-nucleotide phosphodiesterase activity is a molecular_function term, not a cellular component or biological process.
• The activity is classically associated with the cGMP-stimulated PDE family, including PDE2A, which is a major drug target in cardiovascular and neurological disease.
• The reaction requires a divalent metal-dependent catalytic mechanism and is allosterically regulated by cGMP binding to a non-catalytic site.
• Dysregulation of cGMP-stimulated phosphodiesterase activity contributes to cancer, inflammation, and cardiovascular pathology.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential for dissecting the causal role of this activity in disease.
Description
GO:0004118, 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity, is a molecular_function term in the Gene Ontology that describes the catalysis of the reaction nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate, where catalytic activity is increased in the presence of cGMP. This activity is central to cyclic nucleotide signaling because it terminates the second-messenger actions of cAMP and cGMP, thereby shaping the amplitude and duration of downstream signals. Researchers study this term to understand how cells decode cyclic nucleotide signals and to identify therapeutic targets for cardiovascular, inflammatory, and neoplastic diseases. The term is distinct from other phosphodiesterase activities because its catalytic rate is specifically enhanced by cGMP, which binds to an allosteric site and relieves autoinhibition. This property makes it a unique node for crosstalk between cGMP and cAMP pathways. The activity has been biochemically characterized in mammalian tissues and is conserved across metazoans. Recent work on cyclic nucleotide phosphodiesterases as drug targets highlights the continued therapeutic interest in this activity. Understanding GO:0004118 requires integrating enzymology, structural biology, and disease models, which is why it remains a focus of molecular pharmacology.
3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity At A Glance
| GO ID | GO:0004118 |
|---|---|
| GO term | 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity |
| Ontology | molecular_function |
| Synonym | (none) |
| Major function | Hydrolysis of nucleoside 3',5'-cyclic phosphates to nucleoside 5'-phosphates, stimulated by cGMP |
| Reaction | nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate |
| Regulation | Positive allosteric regulation by cGMP |
| Cofactor | Divalent metal ions (e.g., Zn2+, Mg2+) required for catalysis |
| Representative enzyme | cGMP-stimulated phosphodiesterase (PDE2 family) |
What Is GO:0004118?
In simple terms, GO:0004118 is the enzyme activity that cuts a cyclic nucleotide ring to produce a linear nucleotide, and this cutting is faster when cGMP is present. The official definition states: Catalysis of the reaction: nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate; catalytic activity is increased in the presence of cGMP. This activity belongs to the phosphodiesterase superfamily and is distinguished by positive allosteric regulation by cGMP. It does not describe a protein or a complex but the catalytic function itself.
Why Is 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity Important in Cell Biology?
GO:0004118 is important because it controls the lifetime of cyclic nucleotides, which are universal second messengers. By hydrolyzing cAMP and cGMP in a cGMP-stimulated manner, this activity integrates signals from nitric oxide and natriuretic peptide pathways with cAMP-dependent processes. Pharmacological modulation of this activity has been pursued for heart failure, pulmonary hypertension, and cognitive disorders. In cancer, cyclic nucleotide phosphodiesterases influence tumor cell proliferation and immune evasion, making this activity a potential therapeutic node. Thus, understanding GO:0004118 is essential for both basic signal transduction research and drug discovery.
• Regulates intracellular levels of cAMP and cGMP, key second messengers.
• Provides crosstalk between cGMP-generating pathways and cAMP signaling.
• Is a validated drug target for cardiovascular diseases such as heart failure.
• Modulates platelet aggregation and vascular tone.
• Influences neuronal plasticity and memory processes.
• Contributes to inflammatory signaling in immune cells.
• Affects tumor cell proliferation and survival in several cancers.
• Is involved in the hydrolysis of cyclic nucleotides beyond cAMP and cGMP, such as cUMP.
• Can be studied using CRISPR models to establish causality in disease.
• Represents a node for understanding phosphodiesterase inhibitor specificity.
Molecular Mechanism of 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity
Substrate recognition and binding
In simple terms: The enzyme grabs a cyclic nucleotide molecule and holds it in place for cutting.
The catalytic domain of cGMP-stimulated phosphodiesterases contains conserved residues that coordinate the cyclic phosphate moiety of nucleoside 3',5'-cyclic phosphates. Substrate binding involves hydrophobic and hydrogen-bonding interactions that position the cyclic phosphate for nucleophilic attack by a water molecule. This step is common to all class I phosphodiesterases and is not rate-limiting under basal conditions.
Catalytic hydrolysis
In simple terms: A water molecule breaks the cyclic ring, turning it into a linear nucleotide.
Catalysis proceeds via a metal-activated water molecule that attacks the phosphorus atom, leading to cleavage of the cyclic phosphate bond and formation of the nucleoside 5'-phosphate product. The reaction requires divalent metal ions, typically Zn2+ and Mg2+, which stabilize the transition state and the leaving group. This hydrolytic mechanism is shared with other cyclic nucleotide phosphodiesterases.
Allosteric activation by cGMP
In simple terms: cGMP binds to a different site on the enzyme and makes the cutting faster.
The defining feature of GO:0004118 is stimulation by cGMP, which binds to a non-catalytic allosteric site (GAF domain) and relieves autoinhibition, increasing catalytic turnover. This positive allosteric regulation allows cGMP to enhance the hydrolysis of both cGMP and cAMP, creating a negative feedback loop and crosstalk between the two pathways. The structural basis involves conformational changes that propagate from the GAF domain to the catalytic domain.
Product release and turnover
In simple terms: After cutting, the linear nucleotide leaves the enzyme so it can act again.
Following hydrolysis, the nucleoside 5'-phosphate product is released from the active site, allowing the enzyme to bind new substrate. Product release can be influenced by the allosteric state of the enzyme and by interactions with regulatory proteins. The overall turnover rate determines the duration of cyclic nucleotide signals in cells.
Substrate specificity and broader cyclic nucleotide hydrolysis
In simple terms: The enzyme can cut several types of cyclic nucleotides, not just cAMP and cGMP.
While cAMP and cGMP are the best-characterized substrates, cGMP-stimulated phosphodiesterase activity can also hydrolyze other cyclic nucleotides such as cUMP, as shown for PDE3B. This broader specificity suggests roles in pyrimidine cyclic nucleotide signaling. The catalytic mechanism is conserved, but affinity varies among substrates.
Key Genes Involved in GO:0004118 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity
The following genes encode proteins that exhibit or regulate 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PDE2A | cGMP-stimulated phosphodiesterase; hydrolyzes cAMP and cGMP | Major drug target in cardiovascular and CNS disorders |
| PDE3B | cGMP-inhibited phosphodiesterase; can hydrolyze cUMP | Metabolic and cardiovascular research |
| PDE1A | Calmodulin-dependent phosphodiesterase | Neuronal signaling and cardiovascular function |
| PDE1B | Calmodulin-dependent phosphodiesterase | Neurodegeneration and psychiatric disorders |
| PDE1C | Calmodulin-dependent phosphodiesterase | Vascular and airway smooth muscle |
| PDE4A | cAMP-specific phosphodiesterase | Inflammation and cognition |
| PDE4B | cAMP-specific phosphodiesterase | Inflammation and cancer |
| PDE4D | cAMP-specific phosphodiesterase | Cardiovascular and metabolic disease |
| PDE5A | cGMP-specific phosphodiesterase | Erectile dysfunction and pulmonary hypertension |
| PDE6A | Photoreceptor cGMP phosphodiesterase | Retinal degeneration |
| PDE6B | Photoreceptor cGMP phosphodiesterase | Retinitis pigmentosa |
| PDE7A | cAMP-specific phosphodiesterase | Immune and neurological research |
| PDE7B | cAMP-specific phosphodiesterase | Metabolic and CNS research |
| PDE8A | cAMP-specific phosphodiesterase | Thyroid and cancer research |
| PDE8B | cAMP-specific phosphodiesterase | Endocrine and metabolic research |
| PDE9A | cGMP-specific phosphodiesterase | Cognitive disorders |
| PDE10A | cAMP/cGMP phosphodiesterase | Schizophrenia and Huntington disease |
| PDE11A | cAMP/cGMP phosphodiesterase | Adrenal and prostate biology |
How Is 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity Regulated?
The activity of 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase is regulated at multiple levels. Allosteric binding of cGMP to GAF domains directly stimulates catalytic activity. Post-translational modifications such as phosphorylation can modulate enzyme localization and interaction with signaling complexes. Transcriptional regulation of PDE genes alters cellular capacity for cyclic nucleotide hydrolysis. Compartmentalization via scaffolding proteins and membrane association further controls access to substrates. In disease states, changes in cGMP production by soluble guanylate cyclase or particulate guanylate cyclase indirectly regulate this activity.
3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PDE2A | Heart failure, pulmonary hypertension, cognitive disorders | Pde2a knockout and knock-in mouse models |
| PDE3B | Metabolic syndrome, cardiovascular disease | Pde3b knockout mice and cell lines |
| ENPP1 | Breast cancer immune evasion, radiation enteritis | Enpp1 knockout tumor models |
| PDE4D | Cardiovascular disease, depression | Pde4d knockout and overexpression models |
| PDE5A | Erectile dysfunction, pulmonary hypertension | Pde5a knockout mice |
Cardiovascular disease
cGMP-stimulated phosphodiesterase activity is implicated in heart failure and pulmonary hypertension because it modulates cAMP and cGMP levels in cardiomyocytes and vascular smooth muscle. Inhibitors of PDE2A, which exhibits this activity, have been explored for enhancing cyclic nucleotide signaling. Dysregulation can contribute to pathological remodeling and impaired contractility.
Cancer
Cyclic nucleotide phosphodiesterases, including cGMP-stimulated activities, influence tumor cell proliferation, apoptosis, and immune evasion. ENPP1, which hydrolyzes cGAMP, is an innate immune checkpoint in breast cancer, highlighting the importance of cyclic nucleotide hydrolysis in tumor immunity. Exosomal ENPP1 can hydrolyze cGAMP to inhibit cGAS-STING signaling, linking cyclic nucleotide degradation to immune suppression.
Neurological and psychiatric disorders
PDE2A and related phosphodiesterases are expressed in the brain and regulate memory and mood-related circuits. Altered cGMP-stimulated activity may contribute to cognitive deficits and neurodegenerative processes. Targeting this activity is considered for cognitive enhancement.
Inflammation and immune regulation
Cyclic nucleotide phosphodiesterases shape inflammatory responses by controlling cAMP and cGMP levels in immune cells. The cGAS-STING pathway is modulated by cGAMP hydrolysis, and enzymes with related activities can act as immune checkpoints. This makes cGMP-stimulated phosphodiesterase activity relevant to autoimmune and inflammatory diseases.
From 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of PDE2A alter cGMP-stimulated phosphodiesterase activity? | PDE2A knockout cell line or mouse |
| Does a point mutation in the catalytic domain abolish activity? | CRISPR point-mutation knock-in of catalytic residue |
| Does cGMP binding to GAF domain regulate activity? | Knock-in of GAF domain mutation |
| Where is the enzyme localized in cells? | Tagged knock-in with fluorescent protein |
| Does overexpression of PDE2A reduce cAMP/cGMP levels? | Overexpression cell model |
| Can pharmacological inhibitors selectively block this activity? | Wild-type and mutant enzyme assays |
How to Study the 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phosphodiesterase activity assay | Hydrolysis of cyclic nucleotides | Confirming GO:0004118 in candidate enzymes |
| ELISA for cAMP/cGMP | Intracellular cyclic nucleotide levels | Assessing pathway activity after gene editing |
| CRISPR knockout screen | Gene requirement for activity | Identifying regulators of cyclic nucleotide signaling |
| CRISPR activation screen | Gene sufficiency for activity | Discovering enhancers of phosphodiesterase expression |
| Western blot | Protein expression and phosphorylation | Validating knockout or overexpression |
| Immunofluorescence | Subcellular localization | Determining compartmentalization |
| Mass spectrometry | Cyclic nucleotide species including cUMP | Detecting broader substrate specificity |
| Cryo-EM | Protein structure and conformational changes | Understanding allosteric activation |
Enzymatic activity assays
Cyclic nucleotide phosphodiesterase activity is measured using radiolabeled or fluorescent substrates, with cGMP added to test stimulation. These assays can be performed on cell lysates or purified proteins. They are essential for confirming GO:0004118 in candidate enzymes.
Cyclic nucleotide quantification
Intracellular cAMP and cGMP levels are quantified by ELISA, mass spectrometry, or biosensors to infer phosphodiesterase activity in live cells. Changes in these levels after genetic manipulation indicate functional impact.
CRISPR-based genetic screens
Genome-wide CRISPR knockout or activation screens can identify genes that regulate cyclic nucleotide levels or cGMP-stimulated phosphodiesterase activity. These screens link candidate genes to pathway function.
Structural and biophysical methods
X-ray crystallography, cryo-EM, and surface plasmon resonance reveal how cGMP binding allosterically activates the enzyme. These methods provide mechanistic detail for drug design.
How CRISPR Can Be Used to Study GO:0004118 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity
Knockout
CRISPR knockout of PDE2A or other phosphodiesterase genes eliminates cGMP-stimulated cyclic-nucleotide phosphodiesterase activity, allowing researchers to test its role in cellular responses. Knockout cell lines and mice are used to assess changes in cAMP/cGMP levels and downstream phenotypes.
Point Mutation
Point mutations in the catalytic domain or GAF domain can dissect the contribution of catalysis versus allosteric regulation. CRISPR point-mutation knock-in creates isogenic models to study specific residues.
Knock-in
Knock-in of tagged versions of phosphodiesterases enables localization and interaction studies without altering endogenous regulation. Disease-associated mutations can be introduced to model human pathology.
Overexpression
Overexpression of cGMP-stimulated phosphodiesterases reduces cyclic nucleotide levels and can mimic disease states or test therapeutic hypotheses. Inducible overexpression systems allow temporal control.
How EDITGENE Supports 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity Research
Researchers studying 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity-related genes often need to determine whether a candidate gene is causally involved in a specific signaling or disease phenotype. EDITGENE provides CRISPR-based services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity research.
Frequently Asked Questions About 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity
What is 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity?
It is a molecular function defined by GO:0004118 that catalyzes the hydrolysis of nucleoside 3',5'-cyclic phosphates to nucleoside 5'-phosphates, with increased activity in the presence of cGMP.
What genes are involved in 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity?
The best-characterized gene is PDE2A, which encodes a cGMP-stimulated phosphodiesterase; other phosphodiesterases such as PDE3B can also hydrolyze cyclic nucleotides.
What is the reaction catalyzed by GO:0004118?
The reaction is nucleoside 3',5'-cyclic phosphate + H2O = nucleoside 5'-phosphate, and the rate is stimulated by cGMP.
How is cGMP-stimulated phosphodiesterase activity regulated?
It is allosterically activated by cGMP binding to GAF domains and can be further modulated by phosphorylation and protein interactions.
What diseases are associated with cGMP-stimulated phosphodiesterase activity?
It has been implicated in heart failure, pulmonary hypertension, cognitive disorders, cancer, and inflammation.
How can I study GO:0004118 in the lab?
Common methods include phosphodiesterase activity assays, cyclic nucleotide ELISAs, and CRISPR knockout or overexpression models.
What is the difference between PDE2A and other phosphodiesterases?
PDE2A is uniquely stimulated by cGMP, whereas other families such as PDE4 are cAMP-specific or cGMP-inhibited.
Can CRISPR be used to study cGMP-stimulated phosphodiesterase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are widely used to dissect the function of phosphodiesterases.
What are the substrates of cGMP-stimulated phosphodiesterase?
Both cAMP and cGMP are substrates, and some enzymes can also hydrolyze cUMP.
Why is cGMP-stimulated phosphodiesterase a drug target?
Because it regulates cyclic nucleotide signaling in cardiovascular, neurological, and immune cells, making it attractive for therapeutic intervention.
Conclusion
GO:0004118, 3',5'-cGMP-stimulated cyclic-nucleotide phosphodiesterase activity, is a key enzymatic function that shapes cyclic nucleotide signaling through cGMP-stimulated hydrolysis. Its role in cardiovascular, neurological, and immune biology makes it a compelling target for basic and translational research. CRISPR-based models are powerful tools to establish causality and to test therapeutic hypotheses. Continued study of this activity will advance our understanding of signal transduction and disease.
References
- 1. Kelly MP et al.. 2025. Cyclic nucleotide phosphodiesterases as drug targets.. Pharmacol Rev 77(3):100042 PMID: 40081105
- 2. An Y et al.. 2024. Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS-STING Signaling.. Adv Sci (Weinh) 11(20):e2308131 PMID: 38498770
- 3. Zhou Y et al.. 2024. T Cell-Derived Apoptotic Extracellular Vesicles Hydrolyze cGAMP to Alleviate Radiation Enteritis via Surface Enzyme ENPP1.. Adv Sci (Weinh) 11(31):e2401634 PMID: 38888507
- 4. Wang S et al.. 2023. ENPP1 is an innate immune checkpoint of the anticancer cGAMP-STING pathway in breast cancer.. Proc Natl Acad Sci U S A 120(52):e2313693120 PMID: 38117852
- 5. Appleman MM et al.. 1973. Cyclic nucleotide phosphodiesterases.. Adv Cyclic Nucleotide Res 3:65-98 PMID: 4361529
- 7. Ostermeyer J et al.. 2018. cUMP hydrolysis by PDE3B.. Naunyn Schmiedebergs Arch Pharmacol 391(9):891-905 PMID: 29808231
